Luise Fischer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Luise Fischer has a total of 125 co-authors. Here are the top co-authors by number of shared publications:
- Maximilian Merz
Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
15 shared publications - Klaus Hans Metzeler
Department of Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University Hospital Leipzig, Leipzig, Germany
14 shared publications - Thomas Wiemers
Department of Visceral, Transplantation, Vascular and Thoracic Surgery University Hospital Leipzig Leipzig Germany
14 shared publications - Uwe Platzbecker
Universitätsklinikum Carl Gustav Carus, Dresden, Germany
14 shared publications - Vladan Vucinic
Department for Hematology, Cell Therapy, Hemostaseology and Infectious Diseases, University of Leipzig Medical Center, Leipzig, Germany
14 shared publications - David Fandrei
Department of Hematology, Hemostaseology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
13 shared publications
Latest Publications
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- 23 September 2026
- Published by Springer Nature in Nature Medicine
- p. 1-13
Persistence of mucosal CAR-T cells and inflammatory remodeling in enterocolitis associated with BCMA CAR-T cell therapy
B cell-targeted therapies are expanding across oncologic and autoimmune indications, yet their consequences for mucosal immunity remain incompletely examined. Here we define the pathophysiology of ciltacabtagene autoleucel chimeric antigen receptor (CAR)-T cell-induced enterocolitis (EC) (CAR-TEC)—a severe complication of B cell maturation antigen-targeted CAR-T cell therapy in multiple myeloma. Using single-cell transcriptomics, flow cytometry and tissue imaging of intestinal biopsies from patients with CAR-TEC (n = 10), CAR-T cell-treated controls without EC (n = 7) and healthy volunteers (n = 26), we identify profound depletion of mucosal B cells and plasma cells accompanied by expansion of highly cytotoxic CAR-T cells and inflammatory myeloid, stromal and glial cell remodeling to be associated with CAR-TEC. Cell–cell communication analyses suggest a compensated mucosal state in CAR-T cell-treated controls, telocyte-driven stromal niche dysfunction as noted in CAR-TEC. Interferon- and Janus kinase (JAK) and signal transducer and activator of transcription-associated reprogramming was noted across stromal, endothelial and epithelial compartments, supporting JAK inhibition as a rational, mechanism-based therapeutic strategy. Upadacitinib—an oral selective JAK 1 inhibitor—resulted in clinical, endoscopic and histologic improvement in two people with CAR-TEC. Our findings define CAR-TEC as a multicompartment syndrome of severe mucosal dysregulation with implications for the emerging field of B cell-targeted therapies.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Overview of bridging therapies and clinical characteristics.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Overview of bridging therapies and clinical characteristics.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Detailed overview of all regimens administered as bridging therapy for each patient.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Detailed overview of all regimens administered as bridging therapy for each patient.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Proportion of CAR-positive cells in T cell cultures from day 7 after CAR-T infusion used for the in vitro cytotoxicity assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Proportion of CAR-positive cells in T cell cultures from day 7 after CAR-T infusion used for the in vitro cytotoxicity assay.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S15-S19 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Fig. S15: Gating scheme used for quantification of CAR-T cells. Fig. S16: Gating scheme used for immune checkpoint marker detection on non-transduced and CAR-T cells. Fig. S17: Gating scheme used for T cell subsets. Fig. S18: Gating scheme used for detection of perforin and granzyme B on non-transduced and CAR-T cells. Fig. S19: Gating scheme used for flow cytometry readout of the in vitro cytotoxicity assay.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S15-S19 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Fig. S15: Gating scheme used for quantification of CAR-T cells. Fig. S16: Gating scheme used for immune checkpoint marker detection on non-transduced and CAR-T cells. Fig. S17: Gating scheme used for T cell subsets. Fig. S18: Gating scheme used for detection of perforin and granzyme B on non-transduced and CAR-T cells. Fig. S19: Gating scheme used for flow cytometry readout of the in vitro cytotoxicity assay.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S14 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Fig. S1: PFS analysis of the BsAb vs other bridging groups. Fig. S2: Quantification of CAR-T cells using MFC vs PCR. Fig. S3: Correlation of sBCMA levels with IMWG response criteria. Fig. S4: PFS analysis of patients with higher vs lower than median sBCMA on the day of CAR-T infusion. Fig. S5: Impact of bridging with BsAb vs other BT groups on absolute counts of T cell subsets. Fig. S6: Absolute numbers of CAR-T cells in the bridging groups. Fig. S7: Proportions of CAR-T cells in the samples used for the in vitro cytotoxicity assay per bridging group. Fig. S8: Proportions of naive and memory Tregs in the bridging groups. Fig. S9: Overview of T cell subsets stratified by response to bridging. Fig. S10: Alluvials of T cell subsets among the bridging groups. Fig. S11: Checkpoint marker expression stratified by response to bridging therapy. Fig. S12: Proportions of PD-1+CD4+ and PD-1+CD8+ non-transduced T cells amongst the bridging groups. Fig. S13: Overview of sample numbers in the bridging groups included for single-cell multi-omics sequencing. Fig. S14: Numbers of circulating plasma cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S14 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Fig. S1: PFS analysis of the BsAb vs other bridging groups. Fig. S2: Quantification of CAR-T cells using MFC vs PCR. Fig. S3: Correlation of sBCMA levels with IMWG response criteria. Fig. S4: PFS analysis of patients with higher vs lower than median sBCMA on the day of CAR-T infusion. Fig. S5: Impact of bridging with BsAb vs other BT groups on absolute counts of T cell subsets. Fig. S6: Absolute numbers of CAR-T cells in the bridging groups. Fig. S7: Proportions of CAR-T cells in the samples used for the in vitro cytotoxicity assay per bridging group. Fig. S8: Proportions of naive and memory Tregs in the bridging groups. Fig. S9: Overview of T cell subsets stratified by response to bridging. Fig. S10: Alluvials of T cell subsets among the bridging groups. Fig. S11: Checkpoint marker expression stratified by response to bridging therapy. Fig. S12: Proportions of PD-1+CD4+ and PD-1+CD8+ non-transduced T cells amongst the bridging groups. Fig. S13: Overview of sample numbers in the bridging groups included for single-cell multi-omics sequencing. Fig. S14: Numbers of circulating plasma cells.
- Open Access
- 16 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1319-1334
Impact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- 16 May 2026
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (10) , 1319-1334
Open AccessImpact of Renal Impairment and Lymphodepletion Regimen on Outcomes after CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma
- Open Access
- 17 February 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (4) , 832-836
MyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
- 17 February 2026
- Published by Springer Nature in Leukemia
- Vol. 40 (4) , 832-836
Open AccessMyCARdiac score: integrating cardiac imaging and biomarkers to predict outcomes in RRMM patients receiving cilta-cel
- Open Access
- 18 March 2025
- Published by Springer Nature in Research Square
A longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma
Chimeric Antigen Receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) have transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM). In this study, we present a real world cohort of 61 RRMM patients treated with idecabtagene vicleucel (Ide-cel, n=34) and ciltacabtagene autoleucel (Cilta-cel, n=27). Cilta-cel demonstrated superior complete response (CR) rates (CR: 78% vs. 38%, p < 0.001) and longer progression-free survival (PFS), with a distinct CAR-T expansion profile marked by increased CD4+CAR+/CD8+CAR+ ratio. To gain insights into immune dynamics encompassing CAR-T cell infusion with either product, we developed a longitudinal multi-omics single-cell atlas using 135 peripheral blood samples from 57 of the 61 patients. There was a strong association between CD4+ cytotoxic T cells and treatment with Cilta-cel, CR and CRS occurrence. Analysis of T cell receptor repertoires showed higher clonality in CD4 T cells in CR patients at all time points. CD8 T cells of non-CR patients showed transcriptomic changes in line with impaired effector function after CAR-T infusion. The BCMA expressing circulating plasma cells, B-cells and plasmacytoid dendritic cells were depleted after infusion in a response-dependent manner, with Cilta-cel leading to significantly slower B-cell recovery (p=0.03). Increased soluble BCMA reduction between day 0 and 30 was linked to stronger CAR-T expansion and higher CRP levels, suggesting an association of tumor debulking and systemic inflammation (p < 0.01, respectively). Our analyses provide a comprehensive resource for understanding longitudinal cellular kinetics in RRMM patients treated with BCMA-directed CAR-T cells.
- 18 March 2025
- Published by Springer Nature in Research Square
Open AccessA longitudinal single-cell atlas to predict outcome and toxicity after BCMA-directed CAR T cell therapy in multiple myeloma
Chimeric Antigen Receptor (CAR) T-cell therapies targeting B-cell maturation antigen (BCMA) have transformed the treatment landscape for relapsed/refractory multiple myeloma (RRMM). In this study, we present a real world cohort of 61 RRMM patients treated with idecabtagene vicleucel (Ide-cel, n=34) and ciltacabtagene autoleucel (Cilta-cel, n=27). Cilta-cel demonstrated superior complete response (CR) rates (CR: 78% vs. 38%, p < 0.001) and longer progression-free survival (PFS), with a distinct CAR-T expansion profile marked by increased CD4+CAR+/CD8+CAR+ ratio. To gain insights into immune dynamics encompassing CAR-T cell infusion with either product, we developed a longitudinal multi-omics single-cell atlas using 135 peripheral blood samples from 57 of the 61 patients. There was a strong association between CD4+ cytotoxic T cells and treatment with Cilta-cel, CR and CRS occurrence. Analysis of T cell receptor repertoires showed higher clonality in CD4 T cells in CR patients at all time points. CD8 T cells of non-CR patients showed transcriptomic changes in line with impaired effector function after CAR-T infusion. The BCMA expressing circulating plasma cells, B-cells and plasmacytoid dendritic cells were depleted after infusion in a response-dependent manner, with Cilta-cel leading to significantly slower B-cell recovery (p=0.03). Increased soluble BCMA reduction between day 0 and 30 was linked to stronger CAR-T expansion and higher CRP levels, suggesting an association of tumor debulking and systemic inflammation (p < 0.01, respectively). Our analyses provide a comprehensive resource for understanding longitudinal cellular kinetics in RRMM patients treated with BCMA-directed CAR-T cells.
- Open Access
- 8 January 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Proportion of CAR-positive cells in T cell cultures from day 7 after CAR-T infusion used for the in vitro cytotoxicity assay.
- 8 January 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Bispecific Antibodies as Bridging to BCMA CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma
Proportion of CAR-positive cells in T cell cultures from day 7 after CAR-T infusion used for the in vitro cytotoxicity assay.